Introduction:Lecanemab has shown promise in treating early Alzheimer’s disease(AD),but its safety and efficacy in Chinese populations remain unexplored.This study aimed to evaluate the safety and 6-month clinical out...Introduction:Lecanemab has shown promise in treating early Alzheimer’s disease(AD),but its safety and efficacy in Chinese populations remain unexplored.This study aimed to evaluate the safety and 6-month clinical outcomes of lecanemab in Chinese patients with mild cognitive impairment(MCI)or mild AD.Methods:In this single-arm,real-world study,participants with MCI due to AD or mild AD received biweekly intravenous lecanemab(10 mg/kg).The study was conducted at Hainan Branch,Ruijin Hospital Shanghai Jiao Tong University School of Medicine.Patient enrollment and baseline assessments commenced in November 2023.Safety assessments included monitoring for amyloid-related imaging abnormalities(ARIA)and other adverse events.Clinical and biomarker changes from baseline to 6 months were evaluated using cognitive scales(mini-mental state examination[MMSE],montreal cognitive assessment[MoCA],clinical dementia rating-sum of boxes[CDR-SB]),plasma biomarker analysis,and advanced neuroimaging.Results:A total of 64 patients were enrolled in this ongoing real-world study.Safety analysis revealed predominantly mild adverse events,with infusion-related reactions(20.3%,13/64)being the most common.Of these,69.2%(9/13)occurred during the initial infusion and 84.6%(11/13)did not recur.ARIA-H(microhemorrhages/superficial siderosis)and ARIA-E(edema/effusion)were observed in 9.4%(6/64)and 3.1%(2/64)of participants,respectively,with only two symptomatic cases(one ARIA-E presenting with headache and one ARIA-H with visual disturbances).After 6 months of treatment,cognitive scores remained stable compared to baseline(MMSE:22.33±5.58 vs.21.27±4.30,P=0.733;MoCA:16.38±6.67 vs.15.90±4.78,P=0.785;CDR-SB:2.30±1.65 vs.3.16±1.72,P=0.357),while significantly increasing plasma amyloid-β42(Aβ42)(+21.42%)and Aβ40(+23.53%)levels compared to baseline.Conclusions:Lecanemab demonstrated a favorable safety profile in Chinese patients with early AD.Cognitive stability and biomarker changes over 6 months suggest potential efficacy,though high dropout rates and absence of a control group warrant cautious interpretation.These findings provide preliminary real-world evidence for lecanemab’s use in China,supporting further investigation in larger controlled studies.展开更多
基金supported by grants from the Hainan Province Science and Technology Special Fund(No.ZDYF2024LCLH005)National Natural Science Foundation of China(No.82101477)the 2025 Shanghai Natural Science Foundation(No.25ZR1402333).
文摘Introduction:Lecanemab has shown promise in treating early Alzheimer’s disease(AD),but its safety and efficacy in Chinese populations remain unexplored.This study aimed to evaluate the safety and 6-month clinical outcomes of lecanemab in Chinese patients with mild cognitive impairment(MCI)or mild AD.Methods:In this single-arm,real-world study,participants with MCI due to AD or mild AD received biweekly intravenous lecanemab(10 mg/kg).The study was conducted at Hainan Branch,Ruijin Hospital Shanghai Jiao Tong University School of Medicine.Patient enrollment and baseline assessments commenced in November 2023.Safety assessments included monitoring for amyloid-related imaging abnormalities(ARIA)and other adverse events.Clinical and biomarker changes from baseline to 6 months were evaluated using cognitive scales(mini-mental state examination[MMSE],montreal cognitive assessment[MoCA],clinical dementia rating-sum of boxes[CDR-SB]),plasma biomarker analysis,and advanced neuroimaging.Results:A total of 64 patients were enrolled in this ongoing real-world study.Safety analysis revealed predominantly mild adverse events,with infusion-related reactions(20.3%,13/64)being the most common.Of these,69.2%(9/13)occurred during the initial infusion and 84.6%(11/13)did not recur.ARIA-H(microhemorrhages/superficial siderosis)and ARIA-E(edema/effusion)were observed in 9.4%(6/64)and 3.1%(2/64)of participants,respectively,with only two symptomatic cases(one ARIA-E presenting with headache and one ARIA-H with visual disturbances).After 6 months of treatment,cognitive scores remained stable compared to baseline(MMSE:22.33±5.58 vs.21.27±4.30,P=0.733;MoCA:16.38±6.67 vs.15.90±4.78,P=0.785;CDR-SB:2.30±1.65 vs.3.16±1.72,P=0.357),while significantly increasing plasma amyloid-β42(Aβ42)(+21.42%)and Aβ40(+23.53%)levels compared to baseline.Conclusions:Lecanemab demonstrated a favorable safety profile in Chinese patients with early AD.Cognitive stability and biomarker changes over 6 months suggest potential efficacy,though high dropout rates and absence of a control group warrant cautious interpretation.These findings provide preliminary real-world evidence for lecanemab’s use in China,supporting further investigation in larger controlled studies.
